References
- Fields BN, Knipe DM, Howley PM. Fields virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
- Johnson RW, Alvarez-Pasquin M-J, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv vaccines [Internet] 2015 [cited 2017 Feb 5]; 3(4):109-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26478818; https://doi.org/10.1177/2051013615599151
- Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4(6):e004833; https://doi.org/10.1136/bmjopen-2014-004833
- Leme LEG. Vaccines for preventing herpes zoster in older adults. Sao Paulo Med J [Internet]. 2014; 132(4):255. Available from: http://dev1r2.f1000internal.com/pubmed/ref/25055074; https://doi.org/10.1590/1516-3180.20141324T1
- Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014; 12(3):197-210; PMID:24509782; https://doi.org/10.1038/nrmicro3215
- Arvin AM. Humoral and Cellular Immunity to Varicella‐Zoster Virus: An Overview. J Infect Dis [Internet]. 2008 [cited 2017 Jan 7]; 197(s2):S58-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18419410; https://doi.org/10.1086/522123
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE et al. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. N Engl J Med. 2012;367(14):1287-96; PMID:22920912. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa051016#t=article; https://doi.org/10.1056/NEJMoa1208410
- Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis [Internet] 2009 [cited 2017 Jan 11]; 200(7):1068-77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19712037; https://doi.org/10.1086/605611
- Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. [Internet]. J Infect Dis 2008 197:825-35. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 4014857&tool = pmcentrez&rendertype = abstract; https://doi.org/10.1086/528696
- Webster A, Grint P, Brenner MK, Prentice HG, Griffiths PD. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol [Internet] 1989 [cited 2017 Mar 28]; 27(2):117-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2537881; https://doi.org/10.1002/jmv.1890270209
- Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, et al. Decline in Varicella-Zoster Virus (VZV)–Specific Cell-Mediated Immunity with Increasing Age and Boosting with a High-Dose VZV Vaccine. J Infect Dis 188(9):1336-44; [cited 2017 Mar 28]; Available from: https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jid/188/9/10.1086/379048/2/188-9-1336.pdf?Expires = 1491009616&Signature = dmhRqhaBOr9sdPInUt9AryTr4YtuDY9liJNqare79M4ySvRkIKfeLzG7cLdJaO∼QqZQjmqUfBNRFQmV6uYR7whnWOktPdjqV1Yj7vP1k8∼ETkBn21BJ∼.
- Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 Suppl 1:S2-7; https://doi.org/10.1016/S1386-6532(10)70002-0
- Galil K, PW C, JG D, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997; 157(11):1209-13; https://doi.org/10.1001/archinte.1997.00440320105010
- Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Syst Rev 2014; 2:CD006866; https://doi.org/10.1002/14651858.CD006866.pub3
- Lin F, Hadler JL, Hadler J. Epidemiology of Primary Varicella and Herpes Zoster Hospitalizations: The Pre–Varicella Vaccine Era. J Infect Dis 181(6):1897-905; [cited 2017 Mar 28]; Available from: https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jid/181/6/10.1086/315492/2/181-6-1897.pdf?Expires = 1491010315&Signature = RIB∼EGxxkopg8rYJzTqtKZI7OB0-82DmQRgL9ukCxR281-c8D42kanGUxELT5hF9K1BY01p7ZJioW-dsUz52kAR29n9G43wBmVNgbRT8lV9IROQihuOgybyW2AqYspPHF91l27∼MiZ-fcL44AfvQQNu7j3I0FhCmprcb5Pq89YhZ6IMDHytGLF4UMH32Vw9UILrpuMmYCUyvPPSyizA5Bg5RSkVO2JzhEC4Nt72PrFEqYfkbLs1174CeufKNonl∼emIJxmm2Xb87IY8O1xpL5Da3lZylSr3mm7wd56EaQ6GjqhAJ3DNHEOIV∼h4MYxSoea-cg7K9q-xLOtBjvNF4wA__&Key-Pair-Id = APKAIUCZBIA4LVPAVW3Q.
- Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 304(7892):1288-90; https://doi.org/10.1016/S0140-6736(74)90144-5
- Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurol. 1995; 45(12 Suppl 8):S41-6; https://doi.org/10.1212/WNL.45.12_Suppl_8.S41
- Hope-Simpson RE. The Nature of Herpes Zoster: A Long-term Study and a New Hypothesis. Proc R Soc Med. 1965; 58(1):9-20
- Gagliardi AM, Andriolo BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. In: Gagliardi AM, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2016 [cited 2017 Mar 27]. p. CD008858. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26937872.
- Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis [Internet]. 2012 [cited 2017 Mar 27]; 55(10):1320-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22828595; https://doi.org/10.1093/cid/cis638
- Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term Persistence of Zoster Vaccine Efficacy. Clin Infect Dis [Internet] 2015 [cited 2017 Mar 27]; 60(6):900-9; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25416754; https://doi.org/10.1093/cid/ciu918
- Mo C, Lee J, Sommer M, Grose C, Arvin AM. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology 2002; 304(2):176-86; https://doi.org/10.1006/viro.2002.1556
- Dubey L, Steinberg SP, LaRussa P, Oh P, Gershon AA. Western blot analysis of antibody to varicella-zoster virus. J Infect Dis [Internet] 1988 [cited 2017 Jan 15]; 157(5):882-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2834466; https://doi.org/10.1093/infdis/157.5.882
- Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, Wittek AE, Diaz PS. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol [Internet]. 1986 [cited 2017 Jan 7]; 137(4):1346-51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3016094.
- Grose C. Glycoproteins Encoded by Varicella-Zoster Virus: Biosynthesis, Phosphorylation, and Intracellular Trafficking. Annu Rev Microbiol [Internet] 1990 [cited 2017 Jan 7]; 44(1):59-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2174668; ; https://doi.org/10.1146/annurev.mi.44.100190.000423
- Haumont MM, Jacquet A, Massaer M, Deleersnyder V, Mazzu P, Bollen A, Jacobs P. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res 1996; 40(2):199-204; https://doi.org/10.1016/0168-1702(95)01270-2
- Jacquet A, Haumont M, Massaer M, Garcia L, Mazzu P, Daminet V, Grégoire D, Jacobs P, Bollen A. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 2002; 20(11–12):1593-602; PMID:11858867
- Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine [Internet]. 1997 [cited 2017 Jan 15]; 15(9):1001-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9261947; https://doi.org/10.1016/S0264-410X(96)00293-9
- Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines [Internet] 2007 [cited 2017 Jan 15]; 6(5):723-39; Available from: http://www.tandfonline.com/doi/full/10.1586/14760584.6.5.723.
- Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol [Internet] 2007 [cited 2017 Jan 15]; 5(7):505-17. Available from: http://www.nature.com/doifinder/10.1038/nrmicro1681; https://doi.org/10.1038/nrmicro1681
- Stassijns J, Bollaerts K, Baay M, Verstraeten T. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine [Internet]. 2016 Feb 3 [cited 2017 Jan 15];34(6):714-22. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410×1501796X; https://doi.org/10.1016/j.vaccine.2015.12.024
- RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. Krishna S, editor. PLoS Med [Internet] 2014 [cited 2017 Jan 15]; 11(7):e1001685. Available from: http://dx.plos.org/10.1371/journal.pmed.1001685.
- Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012; 30:3126-35; PMID:22326899; https://doi.org/10.1016/j.vaccine.2012.01.088
- Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis [Internet] 2012; 206(8):1280-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22872734; https://doi.org/10.1093/infdis/jis497
- Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study. Vaccine [Internet]. 2014; 32(15):1745-53. Available from: https://doi.org/10.1016/j.vaccine.2014.01.019; https://doi.org/10.1016/j.vaccine.2014.01.019
- Chlibek R, Bayas JM, Collins H, De La Pinta MLR, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. J Infect Dis. 2013; 208(12):1953-61; PMID:23904292; https://doi.org/10.1093/infdis/jit365
- Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine [Internet] 2016; 34(6):863-8. Available from: https://doi.org/10.1016/j.vaccine.2015.09.073; https://doi.org/10.1016/j.vaccine.2015.09.073
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med [Internet] 2015; 372(22):2087-96. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1501184%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/25916341; https://doi.org/10.1056/NEJMoa1501184
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med [Internet] 2016; 375(11):1019-32. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1603800; https://doi.org/10.1056/NEJMoa1603800
- Moanna A, Rimland D. Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis [Internet] 2013 [cited 2017 Jan 15]; 57(1):122-5. Available from: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/cit165; https://doi.org/10.1093/cid/cit165
- Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: A phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015; 211(8):1279-87; PMID:25371534
- Leung TF, Chik KW, Li CK, Lai H, Shing MM, Chan PK, Lee V, Yuen PM. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant [Internet] 2000 [cited 2017 Jan 15]; 25(2):167-72. Available from: http://www.nature.com/doifinder/10.1038/sj.bmt.1702119; https://doi.org/10.1038/sj.bmt.1702119
- Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young JA, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood [Internet]. 2014 [cited 2017 Jan 15]; 124(19):2921-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25237196; https://doi.org/10.1182/blood-2014-04-573048
- Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002. J Infect Dis [Internet]. 2005 [cited 2017 Feb 5]; 191(12):2002-7. Available from: https://academic.oup.com/jid/article-lookup/doi/10.1086/430325; https://doi.org/10.1086/430325